Latest by Barbara Jungwirth
May 30, 2019: Myocardial infarction risk among people with HIV; dolutegravir vs. efavirenz; a new way to estimate date of seroconversion; identifying people at imminent risk for disengagement from care.
May 23, 2019: How CD4 variables over time affect anal cancer risk; when to consider anal pap smears for women; switching from E/C/F/TAF to ABC/3TC; new data on marijuana use among people with HIV.
Authors of a literature review note the high prevalence of liver disease among people with HIV and recommend a step-by-step approach to management.
May 16, 2019: The dwindling value of baseline genotype testing; severe insomnia and cardiovascular disease; cardiovascular risk stratified by sex among people over 50; the persistence of racial disparities among women diagnosed with HIV.
May 9, 2019: HIV care retention and viral suppression among transgender women; heating opioid use equipment to curb HIV transmission; managing HIV outbreaks among people who are homeless; improving viral suppression among people who use substances.
May 2, 2019: patient-centered care model improves viral suppression; subpar immune responses when baseline CD4 tops 500; when CD4 plummets despite viral suppression; vaccination, immunoglobulin, and hepatitis A exposure.
April 25, 2019: stigma and viral load among African-American women; U.S. HIV incidence sans racial disparities; the care continuum is failing young MSM; a moment of reckoning regarding HIV among U.S. youth.
A new study demonstrates the phenomenon, but experts say more research needs to determine why it occurs -- and what researchers can do differently to reduce it.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.